All In Biotech

Drug Trial Radar · NCT04881825

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

84

Actual

Start

Jun 16, 2021

Primary completion

Apr 30, 2026

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Zealand PharmaIndustry
Sponsor type
Industry
First posted
May 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is an extension trial to EASE SBS 2. The study looks at whether glepaglutide is a safe treatment for participants with Short Bowel Syndrome (SBS), as well as how well effectiveness is maintained during long term treatment. Participants in this trial will receive glepaglutide as once-weekly injections under the skin (subcutaneous, s.c.) for approximately 2 years.

Conditions

  • Short Bowel Syndrome

Interventions

  • GlepaglutideDrug

    Glepaglutide will be delivered in a single-use autoinjector.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and type of Adverse Events (AEs)Time frame: After 108 weeks

Locations

19 sites in 8 countries. Site status is shown where the registry gives one.

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Mayo Clinic College of Medicin

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Vanderbilt University Medical Center, Nashville

    Nashville, Tennessee

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

  • Rigshospitalet

    Copenhagen, Denmark

  • Hôpital Beaujon

    Clichy, France

  • Centre Hospitalier Lyon-Sud

    Pierre-Bénite, France

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Bonn

    Bonn, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

  • Asklepios Kliniken Hamburg GmbH

    Hamburg, Germany

  • Universitätsmedizin Rostock

    Rostock, Germany

  • UMC Radboud Nijmegen

    Nijmegen, Netherlands

  • Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi

    Lodz, Poland

  • Szpital Skawina sp. z o.o. im. Stanley Dudricka

    Skawina, Poland

  • St Mark's Hospital

    Harrow, United Kingdom

  • UCLH Foundation NHS Trust

    London, United Kingdom

  • Norfolk and Norwich University Hospitals

    Norwich, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.